12 results
8-K
EX-5.1
ACXP
Acurx Pharmaceuticals, Inc.
17 May 23
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering
4:19pm
to or affect creditors’ rights generally, and (b) general principles of equity (including, without limitation, concepts of materiality, reasonableness, good
8-K
EX-10.1
ACXP
Acurx Pharmaceuticals, Inc.
17 May 23
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering
4:19pm
respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made … be accurate in all material respects (or, as to the extent representations or warranties are qualified by materiality or Material Adverse Effect
PRE 14A
ghs dnsvjj128gqk0sdp
17 Apr 23
Preliminary proxy
4:05pm
8-K
EX-10.1
1klp1esu
25 Jul 22
Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering
8:46am
8-K
EX-5.1
ik1ov6dpq4shvh9rj5u
25 Jul 22
Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering
8:46am
DEF 14A
mvt9tzfm5zvc sws9f
25 Apr 22
Definitive proxy
4:06pm
S-1
EX-10.2
3jgye2y80dp i34pagu
27 May 21
IPO registration
12:00am
DRS/A
EX-10.2
rrs5is
10 May 21
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next